Read articles from Global

August 26, 2026 by washingtonexaminer.com

FDA authorisation of lower-risk nicotine products matters because it gives smokers something more useful than fear. A credible harm reduction framework should recognise products that can reduce exposure to combustion while maintaining strong standards for evidence, marketing and youth protection. The aim is not to normalise nicotine use, but to make the path away from cigarettes more realistic for adults who still smoke. Regulation should reward products that can help reduce harm, not keep the most dangerous option as the easiest one to find.

August 26, 2026 by bbc.com

Nicotine vapes being described as one of the best chances to quit smoking should shift the tone of the debate. Adult smokers need clear advice about options that can move them away from combustible tobacco, not messaging that makes every nicotine product sound equally dangerous. Vaping is not risk-free, but its value lies in comparison with continued smoking. Public health communication should make that hierarchy understandable enough for people to use it.

August 21, 2026 by gfn.tv

A cautious shift in the nicotine debate still matters. Moving the conversation towards safer nicotine products creates space for evidence, consumer experience and the reality that many adults continue to smoke despite repeated quit attempts. Progress does not require abandoning caution; it requires applying it proportionately. The strongest public health position is one that reduces smoking-related harm while keeping regulation honest about differences in risk.

August 20, 2026 by moregoodlessharm.com

AI assistants are becoming part of how people look for health advice, including advice on smoking and vaping. That makes the quality of their answers more than a technical issue: it can shape whether smokers understand relative risk, switching and the dangers of continued combustion. Vague or overly cautious responses may feel safe, but they can leave people with a distorted view of lower-risk alternatives. Digital health information should be accurate, proportionate and clear enough to support real-world harm reduction.

August 17, 2026 by gsthr.org

In its fifth major report, the Global State of Tobacco Harm Reduction (GSTHR) estimates around 200 million people are now using safer nicotine products (SNP), equivalent to a fifth to a quarter of the global smoking population. Analysis shows a consistent pattern of increasing SNP use alongside declining smoking prevalence across 28 countries; in Sweden, Norway, Iceland, New Zealand and the UK, SNP use has overtaken smoking. Meanwhile, global policy has shifted further toward SNP restriction or bans in 2025/6. Published by Knowledge•Action•Change with funding from Global Action to End Smoking, GSTHR: A Situation Report 2026 is out now. https://gsthr.org

August 17, 2026 by gfn.tv

Consumer evidence belongs at the centre of tobacco harm reduction research. Measuring what people think, feel and do helps explain why some products support switching, why others fail, and how regulation affects behaviour outside controlled settings. Numbers alone cannot capture trust, motivation, stigma or product appeal. Better policy needs data on real consumers, not only assumptions about how they should act.

August 10, 2026 by gfn.tv

Nicotine use is not static; people move between products, patterns and levels of risk over time. Understanding how both underage and adult users transition matters because regulation can either guide movement away from harm or unintentionally push it in the wrong direction. For young people, prevention and enforcement remain essential. For adults who smoke, the priority should be making sure product transitions lead away from combustion, not back towards it.

August 10, 2026 by substack.com

An internal memorandum can reveal more than a public statement. It shows how institutions frame risk, manage uncertainty and decide which voices are treated as credible before policy ever reaches the public. In nicotine regulation, that matters because language inside the system can shape whether harm reduction is seen as evidence, threat or inconvenience. Transparency is essential when decisions affect millions of adults who smoke.

August 07, 2026 by gfn.tv

When legal review moves slowly, the market does not wait politely. Delays in the FDA process can leave a void that illicit and unapproved products are quick to fill, while responsible pathways remain blocked or uncertain. That is not only a regulatory problem; it is a consumer protection problem. If safer nicotine products are to replace cigarettes, the legal system must be faster, clearer and capable of keeping people inside accountable markets.

August 07, 2026 by frontiersin.org

Smoking is a major but often neglected driver of poor health among people with schizophrenia spectrum disorders. A 2026 scoping review found preliminary evidence that e-cigarette interventions may be feasible and acceptable in this group, with signs of smoking reduction, short-term abstinence and reduced exposure to tobacco-related carcinogens. The evidence is still limited, with only a small number of studies and important questions about long-term support and generalisability. But for a population where conventional cessation often performs poorly, harm reduction deserves serious clinical attention.